233 related articles for article (PubMed ID: 30264681)
61. Lornoxicam controlled release transdermal gel patch: Design, characterization and optimization using co-solvents as penetration enhancers.
Hashmat D; Shoaib MH; Ali FR; Siddiqui F
PLoS One; 2020; 15(2):e0228908. PubMed ID: 32107483
[TBL] [Abstract][Full Text] [Related]
62. DEVELOPMENT AND EVALUATION OF IVABRADINE HCI-LOADED POLYMERIC MICROSPHERES PREPARED WITH EUDRAGIT L100-55 (METHACRYLIC ACID-ETHYL ACRYLATE COPOLYMER) AND ETHYL CELLULOSE FOR CONTROLLED DRUG RELEASE.
Majeed A; Ranjha NM; Hanif M; Abbas G; Khan MA
Acta Pol Pharm; 2017 Mar; 74(2):565-578. PubMed ID: 29624261
[TBL] [Abstract][Full Text] [Related]
63. Local penetration of doxorubicin via intrahepatic implantation of PLGA based doxorubicin-loaded implants.
Gao L; Li Q; Zhang J; Huang Y; Deng L; Li C; Tai G; Ruan B
Drug Deliv; 2019 Dec; 26(1):1049-1057. PubMed ID: 31691602
[TBL] [Abstract][Full Text] [Related]
64. Ethyl cellulose nanoparticles as a platform to decrease ulcerogenic potential of piroxicam: formulation and in vitro/in vivo evaluation.
El-Habashy SE; Allam AN; El-Kamel AH
Int J Nanomedicine; 2016; 11():2369-80. PubMed ID: 27307735
[TBL] [Abstract][Full Text] [Related]
65. New high throughput screening method for drug release measurements.
Pelczarska A; Delie F; Domańska U; Carrupt PA; Martel S
Eur J Pharm Biopharm; 2013 Sep; 85(1):151-7. PubMed ID: 23958326
[TBL] [Abstract][Full Text] [Related]
66. PLA/F68/dexamethasone implants prepared by hot-melt extrusion for controlled release of anti-inflammatory drug to implantable medical devices: I. Preparation, characterization and hydrolytic degradation study.
Li D; Guo G; Fan R; Liang J; Deng X; Luo F; Qian Z
Int J Pharm; 2013 Jan; 441(1-2):365-72. PubMed ID: 23178216
[TBL] [Abstract][Full Text] [Related]
67. 3-month parenteral PLGA microsphere formulations of risperidone: Fabrication, characterization and neuropharmacological assessments.
Chaurasia S; Mounika K; Bakshi V; Prasad V
Mater Sci Eng C Mater Biol Appl; 2017 Jun; 75():1496-1505. PubMed ID: 28415443
[TBL] [Abstract][Full Text] [Related]
68. Improvement of dissolution rate of piroxicam by inclusion into MCM-41 mesoporous silicate.
Ambrogi V; Perioli L; Marmottini F; Giovagnoli S; Esposito M; Rossi C
Eur J Pharm Sci; 2007 Nov; 32(3):216-22. PubMed ID: 17826966
[TBL] [Abstract][Full Text] [Related]
69. Rheological characterization and in vivo evaluation of thermosensitive poloxamer-based hydrogel for intramuscular injection of piroxicam.
Xuan JJ; Balakrishnan P; Oh DH; Yeo WH; Park SM; Yong CS; Choi HG
Int J Pharm; 2010 Aug; 395(1-2):317-23. PubMed ID: 20573569
[TBL] [Abstract][Full Text] [Related]
70. Polymer based microspheres of aceclofenac as sustained release parenterals for prolonged anti-inflammatory effect.
Kaur M; Sharma S; Sinha VR
Mater Sci Eng C Mater Biol Appl; 2017 Mar; 72():492-500. PubMed ID: 28024613
[TBL] [Abstract][Full Text] [Related]
71. Influence of operational variables on properties of piroxicam pellets prepared by extrusion-spheronization: a technical note.
Sinha VR; Agrawal MK; Kumria R; Bhinge JR
AAPS PharmSciTech; 2007 Mar; 8(1):20. PubMed ID: 17408219
[TBL] [Abstract][Full Text] [Related]
72. Controlled-release implant system formulated using biodegradable hemostatic gauze as scaffold.
Xu L; Wu F; Yuan W; Jin T
Int J Pharm; 2008 May; 355(1-2):249-58. PubMed ID: 18249510
[TBL] [Abstract][Full Text] [Related]
73. In-vitro, ex-vivo, and in-vivo evaluation of buprenorphine HCl release from an in situ forming gel of PLGA-PEG-PLGA using N‑methyl‑2‑pyrrolidone as solvent.
Kamali H; Khodaverdi E; Hadizadeh F; Mohajeri SA
Mater Sci Eng C Mater Biol Appl; 2019 Mar; 96():561-575. PubMed ID: 30606566
[TBL] [Abstract][Full Text] [Related]
74. A potential in situ gel formulation loaded with novel fabricated poly(lactide-co-glycolide) nanoparticles for enhancing and sustaining the ophthalmic delivery of ketoconazole.
Ahmed TA; Aljaeid BM
Int J Nanomedicine; 2017; 12():1863-1875. PubMed ID: 28331311
[TBL] [Abstract][Full Text] [Related]
75. Design of meloxicam and lornoxicam transdermal patches: Preparation, physical characterization, ex vivo and in vivo studies.
Yener G; Üner M; Gönüllü Ü; Yildirim S; Kiliç P; Aslan SS; Barla A
Chem Pharm Bull (Tokyo); 2010 Nov; 58(11):1466-73. PubMed ID: 21048338
[TBL] [Abstract][Full Text] [Related]
76. Concomitant monitoring of implant formation and drug release of in situ forming poly (lactide-co-glycolide acid) implants in a hydrogel matrix mimicking the subcutis using UV-vis imaging.
Sun Y; Jensen H; Petersen NJ; Larsen SW; Østergaard J
J Pharm Biomed Anal; 2018 Feb; 150():95-106. PubMed ID: 29216591
[TBL] [Abstract][Full Text] [Related]
77. Two-Step Sustained-Release PLGA/Hyaluronic Acid Gel Formulation for Intra-articular Administration.
Noda T; Okuda T; Mizuno R; Ozeki T; Okamoto H
Biol Pharm Bull; 2018; 41(6):937-943. PubMed ID: 29863082
[TBL] [Abstract][Full Text] [Related]
78. A pharmaceutical study on lornoxicam fast disintegrating tablets: formulation and in vitro and in vivo evaluation.
Moutasim MY; ElMeshad AN; El-Nabarawi MA
Drug Deliv Transl Res; 2017 Jun; 7(3):450-459. PubMed ID: 28283842
[TBL] [Abstract][Full Text] [Related]
79. Development and validation of a stability indicating HPLC method for the analysis of lornoxicam in powder for injection.
Zhang J; Li L; Gao Y; Fan W
Pak J Pharm Sci; 2012 Apr; 25(2):371-5. PubMed ID: 22459464
[TBL] [Abstract][Full Text] [Related]
80. Impact of in situ granulation and temperature quenching on crystal habit and micromeritic properties of ibuprofen-cationic dextran conjugate crystanules.
Abioye AO; Kola-Mustapha A; Ruparelia K
Int J Pharm; 2014 Feb; 462(1-2):83-102. PubMed ID: 24378327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
